Table 1 List of FDA-Approved Nanomedicines for Cancer Therapy
From: Application of lipid nanovesicle drug delivery system in cancer immunotherapy
Name | Material Description | Nanoparticle Advantage | Indication(s) | Year(s) approved |
|---|---|---|---|---|
Eligard® (Tolmar) | Leuprolide acetate and polymer (PLGH (poly (DL-Lactide-coglycolide)) | Controlled delivery of payload with longer circulation time | Prostate Cancer | 2002 |
DaunoXome® (Galen) | Liposomal Daunorubicin | Increased delivery to tumor site; lower systemic toxicity arising from side-effects | Kaposi’s Sarcoma | 1996 |
Marqibo® (Onco TCS) | Liposomal Vincristine | Increased delivery to tumor site; lower systemic toxicity arising from side-effects | Acute Lymphoblastic Leukemia | 2012 |
Onivyde® (Merrimack) | Liposomal Irinotecan | Increased delivery to tumor site; lower systemic toxicity arising from side-effects | Pancreatic Cancer | 2015 |
Doxil®/Caelyx™ (Janssen) | Liposomal doxorubicin | Improved delivery to site of disease; decrease in systemic toxicity of free drug | Kaposi’s Sarcoma; Ovarian cancer; multiple myeloma | 1995 2005 2008 |
Abraxane®/ABI-007 (Celgene) | Albumin-bound paclitaxel nanoparticles | Improved solubility; improved delivery to tumor | Breast cancer; NSCLC; Pancreatic cancer | 2005 2012 2013 |
Ontak® (Eisai Inc) | Engineered Protein combining IL-2 and diphtheria toxin | Targeted T-cell specificity; lysosomal escape | Cutaneous T-Cell Lymphoma | 1999 |
Nanotherm® (MagForce) | Iron oxide |  | Glioblastoma | 2010 |